corporate information

Growth Initiatives,
Team & Progress

ZIM Labs focuses on multiple business aspects & multi-pronged growth strategy for sustained progress.

growth headline

Growth Initiatives

Business

Salepoint on first service

Research & Development

Market Penetration

development of diffrentiated generics as core offering to:
Enhance product life cycle
Increase patient convenience
Improve adherence to treatment
enhancement of our marketing efforts through
Building marketing partnerships for the pre-formulation intermediates and finished formulations in the RoW & pharmerging markets.
Developing products that are valuable to business partners & patients across markets.
Establishing our presence in the regulated markets through both pharmaceutical & nutraceutical products

Research & Development

  • Enhancing R&D capabilities to eventually launch products in developed markets.
  • Investing more in product development to strengthen the product pipeline.
  • Expanding the portfolio of existing products’ pipeline by adding more novel and differentiated generic products.
  • Increasing investment in innovative process technology platform for continued enabling of differentiated products opportunities

‍

Market Penetration

  • Expanding finished formulation business across several countries in MENA, SEA, CIS, Francophone and LATAM regions.
  • Entering into marketing tie-ups through joint venture arrangements, partnerships, authorizations for specific markets,
    out-licensing of ready dossiers to capture more of the value chain.
  • Launch of ZIM’s brands through own or co-marketing initiatives.
financials

Financial Initiatives

Focused marketing efforts on direct exports of PFI

Formulation Products

Reduction of low margin deemed exports business-particularly from Africa

Direct bidding for higher margin products

Government tenders vs. bidding through third parties

‘Commercialization’ of the OTF
range of products

financials

Financial Statements

Income Statements
Statements of Financial Position
Consolidated Quarterly Income Statements
Particular
FY 2020
FY 2021
FY 2022
FY 2023
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Income from Operations
657
626
692
637
661
834
708
717
630
768
859
1,025
914
977
995
Other Operating
Income
17
52
41
55
44
46
41
22
12
7
8
25
13
17
15
Total Income from Operations
674
678
733
692
705
880
749
739
642
775
867
1,050
927
994
1010
Operating Cost
632
628
647
599
593
751
667
641
577
664
753
886
796
857
855
EBITDA
42
50
86
93
112
129
82
98
65
111
114
164
131
137
155
EBIT
8
16
48
55
73
91
43
56
28
68
75
122
88
93
116
Finance costs
32
32
32
30
29
27
23
30
25
26
18
14
13
14
16
Profit/(Loss) before exceptional item & tax
(24)
(16)
16
25
44
64
20
26
3
42
57
108
75
79
100
Exceptional Item
-
-
-
-
-
52
-
-
-
-
-
-
-
-
-
Profit/(Loss) before tax
(24)
(16)
16
25
44
12
20
26
3
42
57
108
75
79
100
Profit/(Loss) after tax
1
(6)
15
23
33
12
13
15
2
33
41
70
51
55
66
INR in Millions
Consolidated Half Yearly Income Statements
Particular
FY 2020
FY 2021
FY 2022
FY 2023
 H1
 H2
H1
H2
H1
H2
H1
Income from Operations
1,283
1,329
1,495
1,425
1,398
1,884
1,891
Other Operating Income
69
 96
90
63
19 
33
30
Total Income from Operations
1,352
1,425
1,585
1,488
1,417
1,917
1,921
Operating Cost
1,260
1,246
1,344
1,308
1,241
1,639
1,653
EBITDA
92
179
241
180
176
278
268
EBIT
24
103
164
99
96
197
181
Finance costs
64
62
56
53
51
32
27
Profit/(Loss) before exceptional item & tax
(40)
41
108
46
45
165
154
Exceptional Item
-  
-
52
-
-    
-
-
Profit/(Loss) before tax
(40)
41
56
46
45 
165
154
Profit/(Loss) after tax
(5)
38
45
28
35 
111
106
INR in Millions
Consolidated Yearly Income Statements
Particular
FY 2020
FY 2021
FY 2022
Income from Operations
2612
2920
3282
Other Operating Income
165
153
52
Total Income from Operations
2777
3073
3334
Operating Cost
2506
2,652
2,880
EBITDA
271
421
454
EBIT
127
263
293
Finance Costs
126
109
83
Profit/(Loss) before exceptional item & tax
1
154
210
Exceptional Item
-
52
-
Profit/(Loss) before tax
1
102
210
Profit/(Loss) after tax
33
73
146
INR in Millions
Standalone Quarterly Income Statements
Particular
FY 2020
FY 2021
FY 2022
FY 2023
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Income from Operations
652
621
681
624
654
818
701
710
624
751
852
1,016
912
976
988
Other Operating Income
17
52
41
55
44
46
41
22
12
7
8
25
13
15
17
Total Income from Operations
669
673
722
679
698
864
742
732
636
758
860
1,041
925
993
1003
Operating Cost
631
625
647
596
594
751
660
638
574
662
746
888
793
857
852
EBITDA
38
48
75
83
104
113
82
94
62
96
114
153
132
136
151
EBIT
7
17
40
47
68
78
45
55
28
55
79
114
93
95
115
Finance costs
32
32
32
30
29
27
23
30
25
26
18
14
13
14
16
Profit/(Loss) before exceptional item & tax
(25)
(15)
8
17
39
51
22
25
3
29
61
100
80
81
99
Exceptional Item
-
-
-
-
-
52
-
-
-
-
-
-
-
-
-
Profit/(Loss) before tax
(25)
(15)
8
17
39
(1)
22
25
3
29
61
100
80
81
99
Profit/(Loss) after tax
0
(5)
7
15
28
(1)
15
14
2
20
44
64
56
57
66
INR in Millions
Standalone Half Yearly Income Statements
Particular
FY 2020
FY 2021
FY 2022
FY 2023
H1
H2
H1
H2
H1
H2
H1
Income from Operations
1273
1305
1472
1411
1375
1868
1888
Other Operating Income
69
96
90
63
19
33
30
Total Income from Operations
1,342
1,401
1,562
1,474
1,394
1,901
1,918
Operating Cost
1,256
1,243
1,345
1,298
1,236
1,634
1,650
EBITDA
86
158
217
176
158
267
268
EBIT
24
87
146
100
83
193
188
Finance costs
64
62
56
53
51
32
27
Profit/(Loss) before exceptional item & tax
(40)
25
90
47
32
161
161
Exceptional Item
-  
-
52
-
-    
-
-
Profit/(Loss) before tax
(40)
25
38
47
32
161
161
Profit/(Loss) after tax
(5)
22
27
29
22 
108
113
INR in Millions
Standalone Yearly Income Statements
Particular
FY 2020
FY 2021
FY 2022
Income from Operations
2578
2883
3243
Other Operating Income
165
153
52
Total Income from Operations
2743
3036
3295
Operating Cost
2499
2,643
2,870
EBITDA
244
393
425
EBIT
111
246
276
Finance Costs
126
109
83
Profit/(Loss) before exceptional item & tax
(15)
137
193
Exceptional Item
-
52
-
Profit/(Loss) before tax
(15)
85
193
Profit/(Loss) after tax
17
56
130
INR in Millions
Consolidated Quarterly Income Statements
Particular
FY 2020
FY 2021
FY 2022
H1
H2
H1
H2
H1
H2
Income from Operations
1283
1329
1495
1425
1398
1884
Other Operating Income
69
96
90
63
19
33
Total Income from Operations
1,352
1,425
1,585
1,488
1,417
1,917
Operating Cost
1,260
1,246
1,344
1,308
1,241
1,639
EBITDA
92
179
241
180
176
278
EBIT
24
103
164
99
96
197
Finance costs
64
62
56
53
51
32
Profit/(Loss) before exceptional item & tax
(40)
41
108
46
45
165
Exceptional Item
-  
-
52
-
-    
-
Profit/(Loss) before tax
(40)
41
56
46
45 
165
Profit/(Loss) after tax
5
38
45
28
35 
111
Consolidated Quarterly Income Statements
This is some text inside of a div block.
100
100
100
100
100
100
100
100
Consolidated Half Yearly Statements of Financial Positions
Particular
FY 2020
FY 2021
FY 2022
FY 2023
H1
H2
H1
H2
H1
H2
H1
Property, plant and equipment including
Capital work-in-progress
1,114
1,122
1,079
1,052
1,063
1,069
1,075
Intangible assets including Intangible assets under development
128
134
123
120
107
105
129
Other Non- Current Assets
190
177
176
158
127
121
135
Current Assets
1,968
1,820
1,914
1,918
1,931
2,121
2,102
Total assets
3,400
3,253
3,292
3,248
3,228
3,416
3,441
Equity
1,500
1,538
1,579
1,608
1,642
1,757
1,873
Borrowings
907
899
802
811
864
512
633
Other Non- Current Liabilities
4
6
5
2
-
11
34
Current Liabilities
989
810
906
827
722   
1,136
901
Total equity and liabilities
3,400
3,253
3,292
3,248
3,228
3,416
3,441
INR in Millions
Consolidated Yearly Statements of Financial Positions
Particular
FY 2020
FY 2021
FY 2022
Property, plant and equipment including Capital work-in-progress
1,122
1,052
1,069
Intangible assets including Intangible assets under development
134
120
105
Other Non- Current Assets
177
158
121
Current Assets
1,820
1,918
2,121
Total assets
3,253
3,248
3,416
Equity
1,538
1,608
1,757
Borrowings
899
811
512
Other Non- Current Liabilities
6
2
11
Current Liabilities
810
827
1,136
Total equity and liabilities
3,253
3,248
3,416
INR in Millions
Standalone Half Yearly Statements of Financial Positions
Particular
FY 2020
FY 2021
FY 2022
FY 2023
H1
H2
H1
H2
H1
H2
H1
Property, plant and equipment including
Capital work-in-progress
1,114
1,122
1,079
1,052
1,063
1,068
1,074
Intangible assets including Intangible assets under development
79
87
83
84
76
79
108
Other Non- Current Assets
256
257
255
237
207
201
215
Current Assets
1,927
1,763
1,806
1,830
1,821
2,006
1,981
Total assets
3,376
3,229
3,223
3,203
3,167
3,354
3,378
Equity
1,500
1,518
1,544
1,570
1,590
1,701
1,814
Borrowings
907
899
802
811
864
512
633
Other Non- Current Liabilities
4
6
5
2
-
11
34
Current Liabilities
965
806
872
820
713   
1,130
897
Total equity and liabilities
3,376
3,229
3,223
3,203
3,167
3,354
3,378
INR in Millions
Standalone Yearly Statements of Financial Positions
Particular
FY 2020
FY 2021
FY 2022
Property, plant and equipment including Capital work-in-progress
1,122
1,052
1,068
Intangible assets including Intangible assets under development
87
84
79
Other Non- Current Assets
257
237
201
Current Assets
1763
1,830
2,006
Total assets
3229
3,203
3,354
Equity
1,518
1,570
1,701
Borrowings
899
811
512
Other Non- Current Liabilities
6
2
11
Current Liabilities
806
820
1,130
Total equity and liabilities
3,229
3,203
3,354
INR in Millions
BREAKUP OF SALES (INR MN)

Business Mix

‍

Export
Govt/Dom
Deemed Export
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
TECHNOLOGY
CAREERS
CONTACT
PRODUCTS
INVESTORS

© Copyright 2023, ZIM LABORATORIES LIMITED | Disclaimer | QR Scan      |      CIN-L99999MH1984PLC032172